Interstitial cystitis, also known as painful bladder syndrome is a condition that causes painful urinary symptoms that differs from person to person. Mild discomfort, tenderness in the pelvic area, bladder pain and increased frequency to urinate, are some of the observed symptoms in the patients suffering from interstitial cystitis. Irritable bowel syndrome, chronic fatigue syndrome, fibromyalgia and autoimmune diseases are also observed to be associated with interstitial cystitis in the patients. It was estimated that approximately 3.2 to 7.9 million women and 1 to 4 million had the symptoms of interstitial cystitis in the U.S., in 2011. Lipella Pharmaceuticals, Inc. is in the process of developing LP-08 for the treatment of interstitial cystitis. Urigen Pharmaceuticals, Inc. is in the process of developing URG101 for the treatment of the disease. Some of the companies having a pipeline of interstitial cystitis include F Hoffmann-La Roche AG, Tetraphase Pharmaceuticals, Inc., AstraZeneca plc, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.